Diffuse large B-cell lymphoma (DLBCL) is a heterogenous hematological disorder with
malignant potential controlled by immunological characteristics of the tumor …

Background Since their first approval 25 years ago, monoclonal antibodies (mAbs) have
become important targeted cancer therapeutics. However, dermatologic toxicities associated …

Exposure–response (ER) analysis is used to optimize dose and dose regimens during
clinical development. Characterization of relationships between drug exposure and efficacy …

Loncastuximab tesirine is a CD19-directed antibody-drug complex with an alkylating moiety
indicated for third-line treatment of adults with relapsed or refractory large B cell lymphoma …

Tämän arvioinnin kohteena on lonkastuksimabi-tesiriini, joka on tarkoitettu monoterapiana
uusiutuneen tai hoitoon reagoimattoman suurisoluisen B-solulymfooman tai korkean …

Diffuse large B‐cell lymphoma (DLBCL) is an aggressive subtype of non‐Hodgkin
lymphoma with a high rate of disease relapse despite the achievement of clinical responses …

Key elements of scientific writing—consistency and clarity—can be compromised in case of
inaccurate use of methodological terms, especially in complex and multidisciplinary …